BMP2 and Peri-Implantitis: Due to prolonged secretion at a low concentration, BMP2 gene therapy produced significant new bone formation above the peri-implantitis defects, and greater than 70% vertical bone fill was observed; rhBMP-2 therapy for peri-implantitis defects resulted in approximately 30% vertical bone fill24.